New hope for transplant patients with hepatitis b: safer drug switch studied
NCT ID NCT05410496
First seen May 05, 2026 · Last updated May 06, 2026 · Updated 1 time
Summary
This study looks at whether switching to a newer hepatitis B medication (tenofovir alafenamide) is safe and effective for people who have had a kidney or liver transplant. About 52 adult transplant recipients with chronic hepatitis B will be followed to check kidney function, virus levels, and how well they take their medicine. The goal is to see if this switch can better control the virus while protecting the transplanted organ.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC HEPATITIS B are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
China Medical University Hospital
Taichung, 40447, Taiwan
-
Taichung Veterans General Hospital
Taichung, Taiwan, 40705, Taiwan
Conditions
Explore the condition pages connected to this study.